The Biden administration confirmed Tuesday that manufacturers of the 10 prescription drugs earmarked for Medicare price discussions have consented to join the program, potentially heralding lower costs for medications treating diabetes, blood clots, and heart-related conditions. This decision is part of the Inflation Reduction Act, exclusively endorsed by Democrats in Congress in 2022.
Notably, this act aims at decreasing costs for essential drugs and encompasses provisions like capping insulin prices for Medicare beneficiaries at $35/month. The roster of participating drugmakers includes prominent names like Novo Nordisk, Bristol Myers Squibb, and Boehringer Ingelheim. Data from the White House reveals that approximately 9 million Medicare users shelled out over $3.4 billion for these specific medications last year.
President Joe Biden, in his address, emphasized the vital role of affordable medications for countless Americans, reiterating his administration’s relentless pursuit of reduced healthcare expenses. The green light for Medicare’s negotiating power became even more significant following a recent federal court ruling in Ohio, which dismissed a motion by entities including the U.S. Chamber of Commerce that sought to curtail Medicare’s negotiation capabilities. In his address, President Biden voiced his commitment to rebalancing the skewed prescription drug pricing in the U.S, where citizens often pay multiple times more than those in other nations for identical medications.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].